S Moussaoui Selected Research

Stroke (Strokes)

12/2000

The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

S Moussaoui Research Topics

Disease

3	Alzheimer Disease (Alzheimer's Disease) 01/2003 - 02/2000
3	Parkinson Disease (Parkinson's Disease) 04/2001 - 04/2000
1	Vaccine-Preventable Diseases 01/2020
1	Communicable Diseases (Infectious Diseases) 01/2020
1	Antithrombin III Deficiency 03/2017
1	Protein S Deficiency (Deficiency, Protein S) 03/2017
1	Venous Thrombosis (Deep-Vein Thrombosis) 03/2017
1	Cognitive Dysfunction 01/2003
1	Dementia (Dementias) 01/2003
1	Stroke (Strokes) 12/2000
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2000
1	Amyloid Plaque 02/2000

Drug/Important Bio-Agent (IBA)

3	Amyloid beta-PeptidesIBA 01/2003 - 02/2000
3	Proteins (Proteins, Gene)FDA Link 01/2003 - 02/2000
3	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 04/2001 - 04/2000
2	Peptides (Polypeptides)IBA 01/2003 - 06/2001
1	VaccinesIBA 01/2020
1	Factor V (Coagulation Factor V)IBA 03/2017
1	Protein SIBA 03/2017
1	factor V LeidenIBA 03/2017
1	CoagulantsIBA 03/2017
1	Protein CIBA 03/2017
1	Prothrombin (Factor II)IBA 03/2017
1	AnticoagulantsIBA 03/2017
1	ebselenIBA 12/2000
1	Glutathione PeroxidaseIBA 12/2000
1	1-Methyl-4-phenylpyridinium (1 Methyl 4 phenylpyridinium)IBA 12/2000
1	Free RadicalsIBA 12/2000
1	AntioxidantsIBA 12/2000
1	Riluzole FDA LinkGeneric 04/2000
1	PresenilinsIBA 02/2000

Therapy/Procedure

1	Injections 12/2000